Exact Sciences/$EXAS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Exact Sciences
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
Ticker
$EXAS
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
6,950
ISIN
US30063P1057
Website
Exact Sciences Metrics
BasicAdvanced
$9.8B
-
-$5.51
0.92
-
Price and volume
Market cap
$9.8B
Beta
0.92
52-week high
$70.35
52-week low
$39.97
Average daily volume
2.6M
Financial strength
Current ratio
2.727
Quick ratio
2.121
Long term debt to equity
104.404
Total debt to equity
105.932
Interest coverage (TTM)
-6.09%
Profitability
EBITDA (TTM)
38.092
Gross margin (TTM)
69.75%
Net profit margin (TTM)
-36.06%
Operating margin (TTM)
-6.25%
Effective tax rate (TTM)
0.86%
Revenue per employee (TTM)
$410,000
Management effectiveness
Return on assets (TTM)
-1.91%
Return on equity (TTM)
-36.89%
Valuation
Price to revenue (TTM)
3.421
Price to book
4.11
Price to tangible book (TTM)
-10.27
Price to free cash flow (TTM)
49.836
Free cash flow yield (TTM)
2.01%
Free cash flow per share (TTM)
104.76%
Growth
Revenue change (TTM)
11.57%
Earnings per share change (TTM)
315.05%
3-year revenue growth (CAGR)
15.16%
10-year revenue growth (CAGR)
85.79%
3-year earnings per share growth (CAGR)
8.41%
10-year earnings per share growth (CAGR)
14.56%
What the Analysts think about Exact Sciences
Analyst ratings (Buy, Hold, Sell) for Exact Sciences stock.
Bulls say / Bears say
Exact Sciences reported a 10% increase in total revenue for Q4 2024, reaching $713 million, indicating strong financial performance and growth potential. (Exact Sciences Press Release)
The company plans to launch three new cancer tests in 2025—Cologuard Plus™, Oncodetect™, and Cancerguard™—which could significantly expand its product portfolio and market reach. (Exact Sciences Press Release)
Exact Sciences secured favorable Medicare pricing for Cologuard Plus™, enhancing its competitive position and potentially increasing adoption rates among Medicare beneficiaries. (Exact Sciences Press Release)
The company reported a net loss of $865 million in Q4 2024, primarily due to an $838 million impairment charge related to the Thrive acquisition, raising concerns about financial management and profitability. (Exact Sciences Press Release)
Precision Oncology revenue showed minimal growth, increasing only 0.4% in Q4 2024, which may indicate challenges in this segment. (Exact Sciences Press Release)
The upcoming launch of new products like Cancerguard™ faces competition from existing multi-cancer screening tests, potentially impacting market share and revenue growth. (Exact Sciences Press Release)
Data summarised monthly by Lightyear AI. Last updated on 8 Jul 2025.
Exact Sciences Financial Performance
Revenues and expenses
Exact Sciences Earnings Performance
Company profitability
Exact Sciences News
AllArticlesVideos
Exact Sciences Schedules Second Quarter 2025 Earnings Call
Business Wire·4 days ago
Geneoscopy Wins Patent Trial and Appeal Board Decision, Invalidating All 20 Claims of Exact Sciences' '781 Patent
Business Wire·1 week ago
Exact Sciences Announces Medicare Coverage for Oncodetect™ Molecular Residual Disease Test in Colorectal Cancer
Business Wire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Exact Sciences stock?
Exact Sciences (EXAS) has a market cap of $9.8B as of July 18, 2025.
What is the P/E ratio for Exact Sciences stock?
The price to earnings (P/E) ratio for Exact Sciences (EXAS) stock is 0 as of July 18, 2025.
Does Exact Sciences stock pay dividends?
No, Exact Sciences (EXAS) stock does not pay dividends to its shareholders as of July 18, 2025.
When is the next Exact Sciences dividend payment date?
Exact Sciences (EXAS) stock does not pay dividends to its shareholders.
What is the beta indicator for Exact Sciences?
Exact Sciences (EXAS) has a beta rating of 0.92. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.